Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.64 |
| ▸ | RAB9A | P51151 | 3/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.61 |
| ▸ | TP53 | P04637 | 3/20 | 0.61 |
| ▸ | NPC1 | O15118 | 2/20 | 0.61 |
| ▸ | KCNK3 | O14649 | 3/20 | 0.58 |
| ▸ | KCNK9 | Q9NPC2 | 3/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.57 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | AHR | P35869 | 1/20 | 0.54 |
| ▸ | GFER | P55789 | 1/20 | 0.54 |
| ▸ | GLA | P06280 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7636114 | 0.92 | MAPT (0.61) | MAPTSMN1; SMN2RAB9AKMT2AALDH1A1 | |
| SCHEMBL14435720 | 0.90 | MAPT (0.64) | MAPTSMN1; SMN2RAB9AKMT2AALDH1A1 | |
| SCHEMBL2282734 | 0.89 | RAB9A (0.62) | MAPTSMN1; SMN2RAB9AKMT2AALDH1A1 | |
| SCHEMBL14062901 | 0.86 | MAPT (0.67) | MAPTSMN1; SMN2RAB9AKMT2AALDH1A1 | |
| SCHEMBL2060705 | 0.86 | NR1H4 (0.73) | MAPTSMN1; SMN2RAB9AKMT2AALDH1A1 | |
| SCHEMBL5660001 | 0.85 | LMNA (0.63) | MAPTSMN1; SMN2RAB9AALDH1A1MAPK1 | |
| SCHEMBL11479890 | 0.85 | NR1H4 (0.58) | MAPTSMN1; SMN2KMT2AALDH1A1NR1H4 | |
| SCHEMBL2060592 | 0.84 | NR1H4 (0.57) | MAPTSMN1; SMN2KMT2AALDH1A1NPC1 | |
| SCHEMBL2229876 | 0.84 | NPC1 (0.59) | SMN1; SMN2RAB9AKMT2AALDH1A1TP53 | |
| SCHEMBL4428019 | 0.83 | MAPT (0.71) | MAPTSMN1; SMN2RAB9AKMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090281064-A1 | SOLID PHARMACEUTICAL DOSAGE FORMS COMPRISING BISPHOSPHONATES AND MODIFIED AMINO ACID CARRIERS | EMISPHERE TECHNOLOGIES, INC. (US) | 2009-11-12 | — | — | US | claimed |
| WO-2007093226-A1 | ORAL IBANDRONATE FORMULATIONS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-23 | — | — | WO | claimed |
| US-20070049557-A1 | Solid pharmaceutical dosage forms comprising bisphosphonates and modified amino acid carriers | EMISPHERE TECHNOLOGIES, INC. | 2007-03-01 | — | — | US | claimed |
| US-20170189443-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS | PLATINUM MONTAUR LIFE SCIENCES, LLC AND AS AGENT (KY) | 2017-07-06 | — | — | US | disclosed |
| US-20170189443-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS | PLATINUM MONTAUR LIFE SCIENCES, LLC AND AS AGENT (KY) | 2017-07-06 | — | — | US | disclosed |
| US-9370492-B2 | Solid pharmaceutical dosage forms comprising bisphosphonates and modified amino acid carriers | EMISPHERE TECHNOLOGIES, INC. (US) | 2016-06-21 | — | — | US | disclosed |
| US-9370492-B2 | Solid pharmaceutical dosage forms comprising bisphosphonates and modified amino acid carriers | EMISPHERE TECHNOLOGIES, INC. (US) | 2016-06-21 | — | — | US | disclosed |
| US-8785381-B2 | Oral GLP-1 formulations | EMISPHERE TECHNOLOGIES, INC. (US) | 2014-07-22 | — | — | US | disclosed |
| US-8785381-B2 | Oral GLP-1 formulations | EMISPHERE TECHNOLOGIES, INC. (US) | 2014-07-22 | — | — | US | disclosed |
| US-20100016229-A1 | Oral GLP-1 Formulations | NOVO NORDISK NORTH AMERICA OPERATIONS A/S (DK) | 2010-01-21 | — | — | US | disclosed |
| US-20100016229-A1 | Oral GLP-1 Formulations | NOVO NORDISK NORTH AMERICA OPERATIONS A/S (DK) | 2010-01-21 | — | — | US | disclosed |
| US-20090281064-A1 | SOLID PHARMACEUTICAL DOSAGE FORMS COMPRISING BISPHOSPHONATES AND MODIFIED AMINO ACID CARRIERS | EMISPHERE TECHNOLOGIES, INC. (US) | 2009-11-12 | — | — | US | disclosed |
| US-20090281064-A1 | SOLID PHARMACEUTICAL DOSAGE FORMS COMPRISING BISPHOSPHONATES AND MODIFIED AMINO ACID CARRIERS | EMISPHERE TECHNOLOGIES, INC. (US) | 2009-11-12 | — | — | US | disclosed |
| WO-2007093226-A1 | ORAL IBANDRONATE FORMULATIONS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-23 | — | — | WO | disclosed |
| US-20070049557-A1 | Solid pharmaceutical dosage forms comprising bisphosphonates and modified amino acid carriers | EMISPHERE TECHNOLOGIES, INC. | 2007-03-01 | — | — | US | disclosed |
| US-20070049557-A1 | Solid pharmaceutical dosage forms comprising bisphosphonates and modified amino acid carriers | EMISPHERE TECHNOLOGIES, INC. | 2007-03-01 | — | — | US | disclosed |
| US-20070049557-A1 | Solid pharmaceutical dosage forms comprising bisphosphonates and modified amino acid carriers | EMISPHERE TECHNOLOGIES, INC. | 2007-03-01 | — | — | US | disclosed |
| US-20020061311-A1 | Methods and compositions for inducing oral tolerance in mammals | HAAS SUSAN (US) | 2002-05-23 | — | — | US | disclosed |
| US-6391303-B1 | ORALLY ADMINISTERING TO ANIMAL PHARMACEUTICAL FORMULATION COMPRISING ANTIGEN AND DELIVERY AGENT COMPRISING AT LEAST ONE DERIVATIZED AMINO ACID OR SALT THEREOF IN AMOUNT SUFFICIENT TO INDUCE TOLERANCE TO ANTIGEN | EMISPHERE TECHNOLOGIES, INC. | 2002-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281064-A1 | SOLID PHARMACEUTICAL DOSAGE FORMS COMPRISING BISPHOSPHONATES AND MODIFIED AMINO ACID CARRIERS | SLC1A5, SLC7A5, SLC7A1 | MAPT 3605/4885SMN1; SMN2 1235/4885RAB9A 283/4885 |
| US-20070049557-A1 | Solid pharmaceutical dosage forms comprising bisphosphonates and modified amino acid carriers | SLC1A5, SLC7A5, SLC7A1 | MAPT 3604/4885SMN1; SMN2 1232/4885RAB9A 285/4885 |
| US-20170189443-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS | SI, SLC20A1, SLC20A2 | MAPT 3620/4885SMN1; SMN2 366/4885RAB9A 3841/4885 |
| US-20100016229-A1 | Oral GLP-1 Formulations | GLP1R, GIPR, GCGR | MAPT 2851/4885SMN1; SMN2 2041/4885RAB9A 1079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.